Positron emission tomography imaging in dementia

Authors: HERHOLZ, K; CARTER, S F; JONES, M

Source: British Journal of Radiology, Volume 80, Supplement 2, December 2007 , pp. S160-S167(8)

Publisher: British Institute of Radiology

Buy & download fulltext article:

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

Abstract:

Positron emission tomography (PET) is a well-established imaging modality. Measurement of regional cerebral glucose metabolism (rCMRglc) using PET and [18F]-2-fluoro-2-deoxy-d-glucose (FDG) has become a standard technique in both oncology and dementia research. When measuring rCMRglc in Alzheimer's disease (AD), characteristic reductions in rCMRglc are found in neocortical association areas including the posterior cingulate, precuneus, temporoparietal and frontal multimodal association regions; the primary visual cortex, sensorimotor cortex, basal ganglia and cerebellum are relatively unaffected. FDG-PET has been used in the study of mild cognitive impairment (MCI) to accurately predict the subsequent decline to AD. Impairment in rCMRglc may be seen in individuals at high genetic risk of AD, even before clinical symptoms are apparent. Characteristic patterns of regional hypometabolism are also seen in other degenerative dementias such as frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB). The use of different radioisotopes and tracers increases the versatility of PET. Tracers adopted in dementia research include 11C-PK-11195 and 11C-PIB, which have been used to investigate neuroinflammation and amyloid deposition, respectively, in both AD and MCI populations. It is also possible to investigate neurotransmitter systems in dementia; targets have included the cholinergic, dopaminergic and serotonergic systems. Imaging the brains of dementia patients using PET provides important information about the brain function of these individuals that would otherwise be unavailable with other imaging modalities. PET will continue to be important in future dementia research as new tracers become available to help in the early and specific diagnosis of increasingly well-defined clinical syndromes, and assist in the assessment of new therapeutic interventions.

Document Type: Research article

DOI: http://dx.doi.org/10.1259/bjr/97295129

Publication date: 2007-12-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page